IN THE CLAIMS

Please amend the claims as follows:

Claims 1-9 (Canceled).

Claim 10 (New): A substituted isoxazole derivative of the formula I



in which

R^1 is selected from the group consisting of

a) H;

b) C_1-C_6-alkyl which may have 1 or 2 substituents independently of one another selected from the group consisting of NR^4R^5 and OR^6;

c) an aromatic or nonaromatic heterocycle having 5 or 6 ring atoms, including 1, 2 or 3 heteroatoms, independently of one another selected from the group consisting of N, O and S, where the heterocycle may have 1 or 2 substituents independently of one another selected from the group consisting of C_1-C_6-alkyl, halogen, CF_3, OR^6, NR^7R^8, NR^9COR^{10}, a radical of the formula II



and a radical of the formula III



d) phenyl which may have 1, 2 or 3 substituents independently of one another selected from the group consisting of NR^7R^8, OR^6, C_1-C_6-alkyl, halogen, CF_3, CN, NO_2 and CO_2R^6;

e) phenyl-C_1-C_4-alkyl;

f) C_3-C_8-cycloalkyl; and

g) NR^7R^8;

one of the radicals R^2 and R^3 is a radical of the formula IV



in which R^{14} is C_1-C_6-alkyl, halogen, CF_3, OR^6, NR^7R^8, NR^9COR^{10}, a radical of the formula



or a radical of the formula



and

the second of the radicals R^2 and R^3 is

 or  ;

R^4 and R^5 independently of one another are H, C_1-C_6-alkyl, phenyl or phenyl-C_1-C_4-alkyl or together with the nitrogen atom to which they are attached form a saturated 5- or 6-membered heterocycle having 1 or 2 heteroatoms independently of one another selected from the group consisting of N and O;

R^6, R^7 and R^8 independently of one another are H or C_1-C_6-alkyl;

R^9 is H, C_1-C_6-alkyl or benzyl;

R^{10} is C_1-C_6-alkyl, C_3-C_6-cycloalkyl or phenyl which may have 1 or 2 substituents independently of one another, selected from the group consisting of C_1-C_6-alkyl, C_1-C_6-alkoxy and halogen;

R^{11} is H, C_1-C_6-alkyl or phenyl-C_1-C_4-alkyl;

R^{12} and R^{13} independently or one another are H, halogen, C_1-C_6-alkyl or C_1-C_6-alkoxy; and

A is straight-chain or branched C_1-C_6-alkylene; or

an optical isomer or a physiologically acceptable salt thereof.

Claim 11 (New): The compound as claimed in claim 10 where R^2 is 4-fluorophenyl and R^3 is the radical of the formula IV.

Claim 12 (New): The compound as claimed in claim 10 where R^2 is the radical of the formula IV and R^3 is 4-fluorophenyl.

Claim 13 (New): The compound as claimed in claim 10 where R^{14} is selected from the group consisting of halogen, OH, NR^7R^8 and NR^9COR^{10}, where R^7 to R^{10} have the meanings given in claim 1.

Claim 14 (New): The compound as claimed in claim 10 where R^1 is H, phenyl which may have 1 or 2 halogen substituents, NR^7R^8 or C_1-C_6-alkyl, where R^7 and R^8 have the meanings given in claim 1.

Claim 15 (New): The compound as claimed in claim 10 where R^1 is C_1-C_6-alkyl which is substituted by NR^4R^5 or OR^6, an aromatic heterocyclic radical having 5 or 6 ring atoms including 1 or 2 heteroatoms independently of one another selected from the group consisting of N and O, where the heterocycle is optionally substituted by NR^9COR^{10}, phenyl which is optionally substituted by NR^7R^8 or C_1-C_6-alkoxy, NR^7R^8 or C_3-C_6-cycloalkyl.

Claim 16 (New): A pharmaceutical composition comprising at least one compound as claimed in claim 10, if appropriate together with one or more pharmaceutically acceptable carriers and/or additives.

Claim 17 (New): A method for treating immunologically mediated inflammatory diseases, wherein an amount of a compound of the formula I as claimed in claim 10 sufficient to have immunomodulating action and/or to inhibit the release of cytokine is administered to a person in need of such a treatment.